{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-087375","form_type":"8-K","ticker":"RYTM","cik":"0001649904","company_name":"RHYTHM PHARMACEUTICALS, INC.","filed_at":"2023-08-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.682557+00:00","generated_at":"2026-06-12T08:32:52.687986+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"Rhythm Pharma amends exec comp; CEO base $717k, severance enhanced for change of control","bullets":["CEO Meeker: base salary $717,254, bonus target 65%, severance 12 months (18 months +150% bonus on change in control).","CFO Smith: base $480,000, bonus 40%, severance 9 months (12 months +100% bonus under change in control).","CTO Shulman ($435,000) and EVP Chien ($473,000) receive similar amended terms.","Severance conditioned on release of claims and continued compliance with restrictive covenants.","280G best-pay provision ensures after-tax maximization if excise tax applies."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-087375","json":"https://secwatch.observer/filing/0001104659-23-087375.json","markdown":"https://secwatch.observer/filing/0001104659-23-087375.md","text":"https://secwatch.observer/filing/0001104659-23-087375.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1649904/000110465923087375/0001104659-23-087375-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1649904/000110465923087375/tm2322430d2_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T08:32:52.687986+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}